SGLT2 + GLP-1 =

Poll

Combination therapy with an SGLT2 inhibitor and GLP-1 receptor agonist:

A. Is safe and well tolerated
B. Achieves double the weight loss of a SGLT2 inhibitor alone
C. Is additive with respect to its effects on weight loss.
D. All of the above
E. None of the above
Recent Videos
Brendon Neuen, MBBS, PhD | Credit: X.com
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Atul Malhotra, MD | Credit: Kyle Dykes; UC San Diego Health
Optimizing Diabetes Therapies with New Classifications
Should We Reclassify Diabetes Subtypes?
Roger S. McIntyre, MD: GLP-1 Agonists for Psychiatry?
Daniel Gaudet, MD, PhD | Credit: American College of Cardiology
Related Content
Alie Rezaie, MD | Credit: Cedars-Sinai

Surge in New GLP-1 Prescriptions Driven by Semaglutide's Popularity, Study Shows

Patrick Campbell
July 22nd 2024
Article
John Buse, MD, PhD | Credit: UNC School of Medicine

Diabetes Dialogue: CATALYST Trial and Hypercortisolism in T2D, with John Buse, MD, PhD

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES;Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
July 15th 2024
Podcast
FDA Issues CRL to Once-Weekly Insulin Icodec | Image Credit: US Food and Drug Administration

FDA Issues Complete Response Letter for Once-Weekly Insulin Icodec

Connor Iapoce
July 11th 2024
Article
Diabetes Dialogue: ADA 2024 Diabetes Technology Recap

Diabetes Dialogue: ADA 2024 Diabetes Technology Recap

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES;Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
July 3rd 2024
Podcast
Nicholas Stucky, MD, PhD | Credit: LinkedIn

Tirzepatide Bests Semaglutide in Real-World Weight Loss Analysis

Patrick Campbell
July 8th 2024
Article
HCPLive Endocrinology Month In Review June 2024 Thumbnail

Endocrinology Month in Review: June 2024

Patrick Campbell
July 5th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.